Current Report Filing (8-k)
25 June 2022 - 6:32AM
Edgar (US Regulatory)
0001782107
false
0001782107
2022-06-24
2022-06-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 24, 2022
Blue Water Vaccines Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-41294 |
|
83-2262816 |
(State or other Jurisdiction of
Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
201 E. Fifth Street, Suite 1900 Cincinnati, Ohio |
|
45202 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (513) 620-4101
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
|
Trading Symbol(s) |
|
Name of Each Exchange on Which
Registered |
Common Stock, par value $0.00001 per share |
|
BWV |
|
The Nasdaq Stock Market LLC |
Emerging growth
company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other Events.
Due
to delays caused by manufacturing, disruptions relating to suppliers, and those caused by the global COVID-19 pandemic, the Companyhas
adjusted the estimated timeline previously reported in its public filings with respect to the development of its vaccine candidates, BWV-102
and BWV-302 to account for additional time needed to optimize vaccine platform approach and perform sufficient preclinical studies. An
updated summary of the Company’s pipeline for all vaccine candidates is provided as follows:
The
FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development
and regulatory approval of our vaccine candidates. Our vaccine candidates are in early stages of development and may fail in
development or suffer delays that materially and adversely affect their commercial viability. We may be unable to complete
development of or commercialize our vaccine candidates or experience significant delays in doing so due to regulatory or other
uncertainties.
Additional
details regarding the Company and its vaccine candidates are available in the Company’s updated corporate presentation, which is
attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Blue Water Vaccines Inc. |
|
|
|
Date: June 24,
2022 |
By: |
/s/
Joseph Hernandez |
|
|
Joseph Hernandez |
|
|
Chief Executive Officer |
2
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Sep 2024 to Oct 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Oct 2023 to Oct 2024